...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Porcine health management. >Comparison of Mycoplasma hyopneumoniae and porcine circovirus 2 commercial vaccines efficacy when applied separate or combined under experimental conditions
【24h】

Comparison of Mycoplasma hyopneumoniae and porcine circovirus 2 commercial vaccines efficacy when applied separate or combined under experimental conditions

机译：在实验条件下分离或组合时，支原体剪液杂蛋白和猪循环血管2商业疫苗疗效的比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Mycoplasma hyopneumoniae (Mhyo) and Porcine circovirus 2 (PCV-2) are two of the most significant infectious agents causing economic losses in the weaning to slaughter period. Due to their similar vaccination age, the objective of this study was to assess the efficacy of two already existing Mhyo (Hyogen?) and PCV-2 (Circovac?) vaccines when administered separately or combined (RTM) by means of Mhyo or PCV-2 experimental challenges.ResultsSeven groups of animals were included in the study, being three of them challenged with PCV-2, three with Mhyo and one composed of non-challenged, non-vaccinated pigs. Within each experimental challenge, non-vaccinated (NV) groups were compared with double vaccinated groups using the commercial products separated (VS) or combined (VC). Both vaccinated groups showed significant differences for most parameters measured regarding PCV-2 (serology, percentage of infected animals and viral load in tissues) and Mhyo (serology and gross lesions) when compared to NV groups. VS and VC offered similar results, being only significantly different the PCV-2 antibody values at different time points (higher in the VS group) of the study, although not at the termination day (21?days post-PCV-2 inoculation).ConclusionThe present study expands the knowledge on the possibility of using two separate Mhyo and PCV-2 commercial vaccines as a RTM product, which offered equivalent virological, immunological and pathological outcomes as compared to these vaccines when used by separate.
机译：背景技术支原体源性肺炎植物（MHOHO）和猪胃肠病毒2（PCV-2）是最重要的传染性药剂，导致断奶屠宰时期的经济损失。由于其相似的疫苗接种年龄，本研究的目的是评估通过MHYO或PCV-单独或组合（RTM）单独或组合（RTM）时，评估两种已经存在的MHYO（HICOCO）和PCV-2（CIRCOVACα）疫苗的疗效。 2实验挑战。研究中的动物群体包括在研究中，其中三个用PCV-2，三个用MHYO挑战，其中一个由非挑战性的非接种疫苗的猪组成。在每个实验攻击中，使用分离（Vs）或组合（Vc）的商业产品，将非接种疫苗的（NV）组与双疫苗接种基团进行比较。与NV组相比，疫苗接种基团两种疫苗基团对大多数参数显示出对大多数参数的显着差异，与NV基团相比，MHYO（血清素和血清学和血清病变）。 VS和VC提供了类似的结果，在研究中仅在不同时间点（VS组中较高）显着不同，尽管不在终止日（PCV-2后21天）。结论本研究扩大了关于使用两种单独的MHYO和PCV-2商业疫苗作为RTM产品的可能性的知识，该产品提供与单独使用时与这些疫苗相比的等效病毒学，免疫学和病理结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号